Skip to content
Open access

AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

Oct 2026 · Mediastinum · Vol 10 · 0 citations

Abstract

Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). Methods This single-arm, phase 2 trial enrolled patients with advanced or unresectable B3-T and TC, without autoimmune disorders and with measurable lesions by RECIST v.1.1 that have progressed following at least one platinum-based chemotherapy. Treatment consisted of lenvatinib (20 mg orally daily) plus pembrolizumab (200 mg iv infusion once every 3 weeks) in 3-week cycles until disease progression, unacceptable toxicity, or a maximum of 35 cycles. Previous treatment with immunotherapy or sunitinib was not allowed. Results From 09/2021 to 02/2024, 43 patients were enrolled. Median age 57 years (33–81); 84% had a TC; Masaoka Koga IVA/B (35%/65%) with ≥3 metastatic sites in 51% of patients (including 37% with liver metastases), and 44.2% received ≥2 prior lines for advanced disease. PD-L1 expression (22C3, n=32) <1%: 53%, 1-49%: 31%; ≥50%: 16%. After a median follow-up of 24.6 months, median PFS was 22.1 months (95% CI: 10.9–25.1), median overall survival (OS) was 40.2 months (95% CI: 19.1-not estimated), and the 36-monht OS rate was 53.0%. In TC, the median PFS and OS were 21.5 and 40.2 months, respectively. Confirmed objective response rate was 25.6% and median duration of response was 19.8 months (95% CI: 6.1-not estimated). Ten patients (23.3%) completed 2 years of treatment. Grade ≥3 treatment-related adverse events occurred in 46.5% of patients and led to treatment discontinuation in 18.6%. Two (4.7%) non-treatment-related grade 5 events were reported. Grade ≥3 immune-related adverse events occurred in six (14%) patients. No meaningful differences in the toxicity profile were observed between patients with B3-T and TC. Conclusions Final PECATI results support lenvatinib plus pembrolizumab as a potential standard treatment for pre-treated advanced B3-T and TC. Toxicity profile was manageable but close monitoring is advised.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.